within Pharmacolibrary.Drugs.ATC.C;

model C01BA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.3266666666666667,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Ajmaline is a class Ia antiarrhythmic agent used primarily for the diagnosis of Brugada syndrome and the management of supraventricular and ventricular arrhythmias. It is administered intravenously for acute arrhythmic events, and orally for long-term therapy in some countries. Ajmaline is not available in the United States but is used in several European and Asian countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects following intravenous administration.</p><h4>References</h4><ol><li><p>Padrini, R, et al., &amp; Ferrari, M (1993). Pharmacokinetics and electrophysiological effects of intravenous ajmaline. <i>Clinical pharmacokinetics</i> 25(5) 408–414. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199325050-00006&quot;>10.2165/00003088-199325050-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8287634/&quot;>https://pubmed.ncbi.nlm.nih.gov/8287634</a></p></li><li><p>Köppel, C, et al., &amp; Martens, F (1989). Pharmacokinetics and antiarrhythmic efficacy of intravenous ajmaline in ventricular arrhythmia of acute onset. <i>European journal of drug metabolism and pharmacokinetics</i> 14(2) 161–167. DOI:<a href=&quot;https://doi.org/10.1007/BF03190857&quot;>10.1007/BF03190857</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2591421/&quot;>https://pubmed.ncbi.nlm.nih.gov/2591421</a></p></li><li><p>Hashimoto, Y, et al., &amp; Yasuhara, M (1986). Pharmacokinetics and antiarrhythmic activity of ajmaline in rats subjected to coronary artery occlusion. <i>British journal of pharmacology</i> 88(1) 71–77. DOI:<a href=&quot;https://doi.org/10.1111/j.1476-5381.1986.tb09472.x&quot;>10.1111/j.1476-5381.1986.tb09472.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3708225/&quot;>https://pubmed.ncbi.nlm.nih.gov/3708225</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01BA05;
